Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 1/2017

01-01-2017 | Clinical Investigation

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion

Authors: Yoshitsugu Saishin, Yuka Ito, Masato Fujikawa, Tomoko Sawada, Masahito Ohji

Published in: Japanese Journal of Ophthalmology | Issue 1/2017

Login to get access

Abstract

Purpose

We compared the efficacy of bimonthly intravitreal injections of ranibizumab (IVR) with that of bimonthly intravitreal injections of aflibercept (IVA) in two prospective, consecutive groups of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO).

Patients and Methods

Eyes with ME after CRVO received either bimonthly IVR (ranibizumab group; n = 13) or IVA (aflibercept group; n = 13) injections and were followed monthly for 6 months. Three patients in the ranibizumab group and two in the aflibercept group were lost to follow-up and excluded from the study. The best-corrected visual acuity (BCVA), central foveal thickness (CFT) on optical coherence tomography, and aqueous vascular endothelial growth factor (VEGF) concentrations were evaluated before and after treatment.

Results

From baseline to month 6, significant improvements occurred in mean logMAR BCVA (ranibizumab group: 0.78–0.47; p < 0.05; aflibercept group: 0.74–0.54; p < 0.05) and mean CFT (ranibizumab group: 685–311 µm; p < 0.05; aflibercept group: 695–230 µm; p < 0.05). Fluctuations in CFT were seen at months 2, 4, and 6 in the ranibizumab group. Mean aqueous VEGF concentration decreased from baseline to month 2 in the ranibizumab group (509.9–348.2 pg/ml) and aflibercept group (412.1 pg/ml to undetectable limits in eight of 11 eyes and to 13.6, 15.6, and 24.1 pg/ml in the other three eyes, respectively).

Conclusions

There was no significant improvement of visual acuity in one group compared with another; VEGF may not be completely neutralized by bimonthly injections of ranibizumab.
Literature
1.
Hayreh SS, Klugman MR, Beri M, Kimura AE, Podhajsky P. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch Clin Exp Ophthalmol. 1990;228:201–17.CrossRefPubMed
2.
McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(1113–23):e15.
3.
Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56:281–99.CrossRefPubMed
4.
Hayreh SS, Podhajsky PA, Zimmerman MB. Natural history of visual outcome in central retinal vein occlusion. Ophthalmology. 2011;118(119–33):e1–2.
5.
Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch Ophthalmol. 2008;126:513–8.CrossRefPubMed
6.
Green WR, Chan CC, Hutchins GM, Terry JM. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Trans Am Ophthalmol Soc. 1981;79:371–422.PubMedPubMedCentral
7.
Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995; 102: 1425-33.
8.
Noma H, Funatsu H, Mimura T, Shimada K. Visual acuity and foveal thickness after vitrectomy for macular edema. Ophthalmologica. 2010;224:367–73.CrossRefPubMed
9.
Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Influence of vitreous factors after vitrectomy for macular edema in patients with central retinal vein occlusion. Int Ophthalmol. 2011;31:393–402.CrossRefPubMed
10.
Weis E, Gan KD, Hinz BJ, Tennant MT, MacDonald IM, Greve MJ. A retrospective cohort study of radial optic neurotomy for severe central retinal vein occlusions. Can J Ophthalmol. 2008;43:73–8.CrossRefPubMed
11.
Aggermann T, Brunner S, Krebs I, Haas P, Womastek I, Brannath W, et al. A prospective, randomised, multicenter trial for surgical treatment of central retinal vein occlusion: results of the Radial Optic Neurotomy for Central Vein Occlusion (ROVO) study group. Graefes Arch Clin Exp Ophthalmol. 2013;251:1065–72.CrossRefPubMed
12.
Ip MS, Scott IU, VanVeldhuisen PC, Oden NL, Blodi BA, Fisher M, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127:1101–14.CrossRefPubMedPubMedCentral
13.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(1134–46):e3.
14.
Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology. 2011;118:2453–60.CrossRefPubMed
15.
Epstein DL, Algvere PV, von Wendt G, Seregard S, Kvanta A. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology. 2012;119:2587–91.CrossRefPubMed
16.
Iturralde D, Spaide RF, Meyerle CB, Klancnik JM, Yannuzzi LA, Fisher YL, et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina. 2006;26:279–84.CrossRefPubMed
17.
Wroblewski JJ, Wells JA 3rd, Adamis AP, Buggage RR, Cunningham ET Jr, Goldbaum M, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol. 2009;127:374–80.CrossRefPubMed
18.
Brown DM, Campochiaro PA, Singh RP, Li Z, Gray S, Saroj N, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(1124–33):e1.
19.
Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118:2041–9.CrossRefPubMed
20.
Risard SM, Pieramici DJ, Rabena MD, Basefsky JC, Avery RL, Castellarin AA, et al. Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31:1060–7.CrossRefPubMed
21.
Spaide RF, Chang LK, Klancnik JM, Yannuzzi LA, Sorenson J, Slakter JS, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol. 2009;147:298–306.CrossRefPubMed
22.
Boyer D, Heier J, Brown DM, Clark WL, Vitti R, Berliner AJ, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119:1024–32.CrossRefPubMed
23.
Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013;97:278–84.CrossRefPubMed
24.
Eadie JA, Ip MS, Kulkarni AD. Response to aflibercept as secondary therapy in patients with persistent retinal edema due to central retinal vein occlusion initially treated with bevacizumab or ranibizumab. Retina. 2014;34:2439–43.CrossRefPubMed
25.
Zhou S, Gao J, Xu X. Antivascular endothelial growth factors in the treatment of macular oedema secondary to central retinal vein occlusion: a meta-analysis. Clin & exp ophthalmol. 2014;42:637–49.CrossRef
26.
Ford JA, Shyangdan D, Uthman OA, Lois N, Waugh N. Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis. BMJ open. 2014;4:e005292.CrossRefPubMedPubMedCentral
27.
Ford JA, Clar C, Lois N, Barton S, Thomas S, Court R, et al. Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ open. 2014;4:e004120.CrossRefPubMedPubMedCentral
28.
Pielen A, Feltgen N, Isserstedt C, Callizo J, Junker B, Schmucker C. Efficacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS ONE. 2013;8:e78538.CrossRefPubMedPubMedCentral
29.
Wang X, Sawada T, Sawada O, Saishin Y, Liu P, Ohji M. Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol. 2014;158(738–44):e1.
30.
Wang X, Sawada T, Kakinoki M, Miyake T, Kawamura H, Saishin Y, et al. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252:1033–9.CrossRefPubMed
31.
Sawada T, Kakinoki M, Wang X, Kawamura H, Saishin Y, Ohji M. Bimonthly injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252:1545–51.CrossRefPubMed
32.
Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci. 2005;46:726–33.CrossRefPubMed
33.
Bakri SJ, Snyder MR, Reid JM, Pulido JS, Ezzat MK, Singh RJ. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 2007;114:2179–82.CrossRefPubMed
34.
Christoforidis JB, Williams MM, Kothandaraman S, Kumar K, Epitropoulos FJ, Knopp MV. Pharmacokinetic properties of intravitreal I-124-aflibercept in a rabbit model using PET/CT. Curr Eye Res. 2012;37:1171–4.CrossRefPubMed
Metadata
Title
Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion
Authors
Yoshitsugu Saishin
Yuka Ito
Masato Fujikawa
Tomoko Sawada
Masahito Ohji
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 1/2017
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-016-0476-7

Other articles of this Issue 1/2017

Japanese Journal of Ophthalmology 1/2017 Go to the issue

Clinical Investigation

Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab

Clinical Investigation

Effect of vitreomacular separation on macular thickness determined by spectral-domain optical coherence tomography

Clinical Investigation

In vivo imaging of a cone mosaic in a patient with achromatopsia associated with a GNAT2 variant

Clinical Investigation

Eyelid cleansing with ointment for obstructive meibomian gland dysfunction

Review

A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases

Clinical Investigation

The effect of the extent of the incision in the Schlemm canal on the surgical outcomes of suture trabeculotomy for open-angle glaucoma